StockNews.com initiated coverage on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a research note published on Wednesday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Several other brokerages have also commented on NKTR. TD Cowen raised shares of Nektar Therapeutics from a market perform rating to an outperform rating […]